EI24 Inhibits Cell Proliferation and Drug Resistance of Esophageal Squamous Cell Carcinoma
Lili Duan(Guizhou University), Daiming Fan(National Clinical Research Center for Digestive Diseases), Lu Cao(Chinese Academy of Sciences), Hongwei Zhang(University of Massachusetts Chan Medical School), Yujie Zhang(University of Chinese Academy of Sciences), Liu Hong(National Clinical Research Center for Digestive Diseases), Xiaoqian Wang(Institute of Basic Medical Sciences of the Chinese Academy of Medical Sciences), Jinqiang Liu(University of California, Irvine), Wanli Yang(National Clinical Research Center for Digestive Diseases), Yiding Li(National Clinical Research Center for Digestive Diseases), Wei Zhou(Broad Institute), Qingchuan Zhao(City University of Hong Kong), Jiaojiao Ma(Sun Yat-sen University), Liaoran Niu(Xijing Hospital)
Cited by 15
Related Papers
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
Antioxidant Phytochemicals for the Prevention and Treatment of Chronic Diseases
|Molecules|2015|1.4k
Resources and Biological Activities of Natural Polyphenols
|Nutrients|2014|891
lncRNA MIR100HG-derived miR-100 and miR-125b mediate cetuximab resistance via Wnt/β-catenin signaling
|Nature Medicine|2017|460
miRNA-223 Promotes Gastric Cancer Invasion and Metastasis by Targeting Tumor Suppressor EPB41L3
|Molecular Cancer Research|2011|361